Topic Hub
43 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 43 of 43 clinical reviews.
Tesamorelin (Egrifta) is not FDA-approved for adolescents aged 12-17. This article covers the adult dosing benchmark, why pediatric data are absent, growth-velocity risks, and clinical alternatives for HIV-associated lipodystrophy in teens.
Read clinical reviewEvidence-based monitoring protocols for tesamorelin (Egrifta) use in adolescents aged 12-17 with HIV-associated lipodystrophy, including IGF-1 tracking, growth velocity, metabolic panels, and mental health screening.
Read clinical reviewA comprehensive clinical review of tesamorelin (Egrifta) safety in adolescents aged 12-17 with HIV-associated lipodystrophy, covering growth effects, metabolic risks, monitoring protocols, and current prescribing guidance.
Read clinical reviewEvidence-based tesamorelin (Egrifta) dosing guide for adults aged 30 to 49, covering standard 2 mg subcutaneous injection protocols, administration technique, monitoring, and dose adjustments.
Read clinical reviewA clinician-grade review of tesamorelin (Egrifta) drug-drug interactions, covering antiretrovirals, cortisol-modulating agents, insulin, and growth hormone axis drugs with cited evidence.
Read clinical reviewCompare the cost of Egrifta (tesamorelin) against alternative GHRH analogs, GH secretagogues, and other treatments for HIV-associated lipodystrophy. Includes pricing data, clinical efficacy comparisons, and insurance coverage guidance.
Read clinical reviewEvidence-based guide to tesamorelin (Egrifta SV) dosing in adults aged 50 to 64, covering standard protocols, age-related pharmacokinetic considerations, IGF-1 monitoring, and safety in the context of polypharmacy and cardiovascular risk.
Read clinical reviewClinical guidance on tesamorelin (Egrifta SV) dosing for patients with hepatic impairment, including pharmacokinetic data, liver safety monitoring, and prescribing considerations for HIV-associated lipodystrophy.
Read clinical reviewEvidence-based guide to tesamorelin (Egrifta) dosing in patients with renal impairment, including pharmacokinetic considerations, GFR thresholds, monitoring parameters, and clinical recommendations for HIV-associated lipodystrophy.
Read clinical reviewComplete guide to tesamorelin (Egrifta) food and supplement interactions, mechanism of action, dosing, and clinical evidence from HIV-associated lipodystrophy trials.
Read clinical reviewA clinical deep dive into tesamorelin's pipeline developments, including oral and long-acting formulations, non-HIV indications under investigation, and what prescribers and patients should expect from upcoming Egrifta research.
Read clinical reviewEvidence-based guide to tesamorelin dosing in adults 65 and older, covering pharmacokinetics, renal considerations, monitoring, and clinical pearls for prescribers managing HIV-associated lipodystrophy in geriatric patients.
Read clinical reviewEvidence-based monitoring protocols for tesamorelin (Egrifta) in adults aged 65 and older with HIV-associated lipodystrophy, covering renal function, glucose metabolism, IGF-1 levels, falls risk, and deprescribing decision points.
Read clinical reviewEvidence-based guide to tesamorelin safety in adults 65 and older, covering dose adjustments, renal monitoring, drug interactions, IGF-1 surveillance, and deprescribing considerations.
Read clinical reviewA comprehensive clinical history of tesamorelin (Egrifta), the synthetic GHRH analog developed by Theratechnologies for HIV-associated lipodystrophy, covering mechanism of action, key trials, and regulatory milestones.
Read clinical reviewEvidence-based guide to tesamorelin use in special populations including HIV-associated lipodystrophy, solid organ transplant recipients, MASLD, and aging adults. Covers dosing, safety signals, and off-label clinical data.
Read clinical reviewA clinical review of tesamorelin (Egrifta) manufacturing by Theratechnologies, its pharmaceutical supply chain, FDA shortage listings, and the evolution from multi-vial to single-vial formulation.
Read clinical reviewA full MD-level breakdown of how tesamorelin (Egrifta) works, from GHRH receptor binding and pulsatile GH release to IGF-1 signaling, lipolysis, and visceral fat reduction in HIV-associated lipodystrophy.
Read clinical reviewEvidence-based guidance on what to do if you miss a dose of tesamorelin (Egrifta SV), including timing rules, clinical pharmacology, and when to contact your prescriber.
Read clinical reviewComplete monitoring guide for tesamorelin (Egrifta) in adults aged 30 to 49 with HIV-associated lipodystrophy. Covers baseline labs, IGF-1 tracking, glucose surveillance, imaging intervals, and when to adjust or stop therapy.
Read clinical reviewEvidence-based monitoring schedule for tesamorelin (Egrifta SV) therapy in HIV-associated lipodystrophy, including IGF-1, glucose, lipids, and imaging timelines.
Read clinical reviewA clinician-reviewed guide to tesamorelin off-label uses beyond HIV lipodystrophy, including evidence levels for cognitive decline, NAFLD, body composition, and more.
Read clinical reviewA comprehensive clinical guide to monitoring tesamorelin (Egrifta) in adults aged 50, 64 with HIV-associated lipodystrophy, covering lab panels, cardiovascular risk, polypharmacy interactions, and age-specific safety checkpoints.
Read clinical reviewEvidence-based guide to tesamorelin (Egrifta) overdose management, accidental excess dosing, expected adverse effects, GH-axis pharmacology, and clinical monitoring after supratherapeutic exposure.
Read clinical reviewA physician-reviewed deep dive into tesamorelin's mechanism, FDA approval history, Orange Book patents, exclusivity cliffs, and the current generic entry timeline for Egrifta SV.
Read clinical reviewTesamorelin (Egrifta) has no FDA-approved pediatric dosing for children under 12. Review the clinical evidence gaps, safety considerations, and what guidelines say about GHRH analog use in this age group.
Read clinical reviewTesamorelin (Egrifta) is not FDA-approved for children under 12. Learn about off-label monitoring protocols, IGF-1 tracking, growth surveillance, and safety considerations for pediatric GHRH analog use.
Read clinical reviewTesamorelin (Egrifta) is not FDA-approved for pediatric use. This evidence-based review covers safety concerns, off-label considerations, growth hormone axis effects, and clinical guidance for children under 12.
Read clinical reviewA clinical-depth review of tesamorelin (Egrifta) pharmacokinetics covering absorption after subcutaneous injection, distribution, proteolytic metabolism, and elimination half-life, with FDA label and PubMed-cited evidence.
Read clinical reviewIs tesamorelin (Egrifta) safe during pregnancy or breastfeeding? Evidence-based review of FDA labeling, animal data, GH-axis effects, and clinical guidance for women of childbearing potential.
Read clinical reviewA clinical review of tesamorelin (Egrifta) real-world evidence from registries, observational cohorts, and post-marketing studies in HIV-associated lipodystrophy and beyond.
Read clinical reviewA comprehensive clinical review of tesamorelin (Egrifta) regulatory approvals, rejections, and compounding status across the US, EU, Canada, and UK, with trial evidence and prescribing context.
Read clinical reviewA clinician-reviewed guide to tesamorelin (Egrifta) safety for adults aged 30 to 49, covering side effects, monitoring, contraindications, and long-term data from key trials.
Read clinical reviewA clinical review of tesamorelin (Egrifta) safety for adults aged 50 to 64, covering cardiovascular risk, IGF-1 monitoring, drug interactions, and age-specific adverse effects.
Read clinical reviewA clinical guide to tesamorelin (Egrifta) safety in young adults aged 18 to 29, covering side effects, monitoring, fertility considerations, and long-term use data for HIV-associated lipodystrophy.
Read clinical reviewA physician-level review of tesamorelin (Egrifta) safety signals, FDA regulatory actions, postmarketing surveillance data, and clinical risk considerations for HIV-associated lipodystrophy treatment.
Read clinical reviewLearn the correct tesamorelin (Egrifta SV) self-injection technique, including reconstitution, site selection, rotation, and troubleshooting. Reviewed by the HealthRX.com medical team.
Read clinical reviewComplete guide to Egrifta (tesamorelin) storage conditions, reconstitution stability, shelf life, and mechanism of action. Reviewed by board-certified physicians with primary-source citations.
Read clinical reviewA physician-level guide to switching tesamorelin (Egrifta) from or to other growth-hormone-releasing hormones, GH secretagogues, and GLP-1 agents in HIV-associated lipodystrophy. Covers mechanism, pharmacology, washout timing, and clinical evidence.
Read clinical reviewEvidence-based guide to tesamorelin dosing in young adults aged 18, 29, covering standard protocols, age-specific considerations, fertility implications, and monitoring parameters for HIV-associated lipodystrophy.
Read clinical reviewA physician-reviewed guide to discontinuing tesamorelin (Egrifta) safely, covering rebound visceral fat, IGF-1 changes, tapering options, and when to restart.
Read clinical reviewEvidence-based monitoring guide for tesamorelin (Egrifta) in young adults aged 18 to 29 with HIV-associated lipodystrophy. Covers baseline labs, follow-up intervals, IGF-1 tracking, metabolic panels, imaging, and fertility considerations.
Read clinical reviewEvidence-based review of tesamorelin pharmacogenomics, including GHRH receptor polymorphisms, GH1 variants, CYP metabolism considerations, and how genetic variability influences Egrifta efficacy in HIV-associated lipodystrophy.
Read clinical review